Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia (CaRD)

This study has been completed.
Onyx Pharmaceuticals
Information provided by (Responsible Party):
Steven P. Treon, MD, PhD, Dana-Farber Cancer Institute Identifier:
First received: September 22, 2011
Last updated: October 31, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2016
  Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):